Construction of an allosteric trans-maxizyme targeting for two distinct oncogenes.
A maxizyme is dimmer of minimized ribozymes (minizymes) and can specifically cleave two target sites. The maxizyme also can allosterically cleave the target RNA only when it recognizes two target sites. In this study, for a cancer gene therapy, we focused two distinct oncogenes, cyclinD1 and hst-1, which are overexpressed in breast cancer cells. If we use conventional ribozymes for suppression of expression of those genes, these ribozymes affect not only these mRNAs in cancer cells but also those in normal cells because those genes are necessary for a growth factor-dependent signal transduction and a cell cycle in normal cells. To overcome this problem, we tried to design the trans-maxizyme that can cleave these mRNAs only in the breast cancer cells.
Iyo
Mayu
M
Department of Chemistry and Biotechnology, School of Engineering, University of Tokyo, 7-3-1 Hongo, Tokyo 113-8656, Japan.
Kawasaki
Hiroaki
H
Taira
Kazunari
K
D000494:Allosteric Regulation; D001483:Base Sequence; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology; D019938:Cyclin D1 / Q000235:genetics; D051519:Fibroblast Growth Factor 4; D005346:Fibroblast Growth Factors / Q000235:genetics; D006801:Humans; D009690:Nucleic Acid Conformation; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016337:RNA, Catalytic / Q000737:chemistry / Q000235:genetics
C496445:FGF4 protein, human; D051519:Fibroblast Growth Factor 4; D011518:Proto-Oncogene Proteins; D016337:RNA, Catalytic; D019938:Cyclin D1; D005346:Fibroblast Growth Factors